Diabetes Metab J.  2019 Dec;43(6):917-918. 10.4093/dmj.2019.0216.

Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)

• Chung YR
• Ha KH
• Lee K
• Kim DJ

• KMID: 2466516
• DOI: http://doi.org/10.4093/dmj.2019.0216

Abstract

No abstract available.

MeSH Terms

Cohort Studies*
Diabetic Retinopathy*
Hypoglycemic Agents*
Metformin*
Hypoglycemic Agents
Metformin

Reference

1. Chung YR, Ha KH, Kim HC, Park SJ, Lee K, Kim DJ. Dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-based cohort study. Diabetes Metab J. 2019; 43:640–648. PMID: 30877707.

2. Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT. Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014; 121:2443–2451. PMID: 25172198.

3. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016; 18:333–347. PMID: 26597596.

4. Kim NH, Choi J, Kim NH, Choi KM, Baik SH, Lee J, Kim SG. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: a population-based study. Diabetes Metab. 2018; 44:361–367. PMID: 29752167.